The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
Open accessAbstract
Calcineurin inhibitors added to standard-of-care induction therapy for lupus nephritis (LN) may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel calcineurin inhibitor voclosporin for efficacy and safety in active LN. AURA-LV was a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, each twice daily) versus placebo in combination with mycophenolate mofetil (2 g/d) and rapidly tapered low-dose oral corticosteroids for induction of remission in LN. The primary endpoint was CRR at 24 weeks; the secondary endpoint was CRR at 48 weeks. Two hundred sixty-five subjects from 79 centers in 20 countries were recruited and randomized to treatment for 48 weeks. CRR at week 24 was achieved by 29 (32.6%) subjects in the low-dose voclosporin group, 24 (27.3%) subjects in the high-dose voclosporin group, and 17 (19.3%) subjects in the placebo group (OR=2.03 for low-dose voclosporin versus placebo). The significantly greater CRR rate in the low-dose voclosporin group persisted at 48 weeks, and CRRs were also significantly more common in the high-dose voclosporin group compared to placebo at 48 weeks. There were more serious adverse events in both voclosporin groups, and more deaths in the low-dose group compared to placebo and high-dose voclosporin groups (11.2%, 1.1%, and 2.3%, respectively). These results suggest that the addition of low-dose voclosporin to mycophenolate mofetil and corticosteroids for induction therapy of active LN results in a superior renal response compared to mycophenolate mofetil and corticosteroids alone, but higher rates of adverse events including death were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationCalcineurin: Form and Function
Rusnak, F., & Mertz, P. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1483 · Cited by 1,373
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citationLevey, A. S., & Stevens, L. A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.337 · Cited by 1,005
Almaani, S., Meara, A., & Rovin, B. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05780616 · Cited by 930
Self-citationCalcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.
Fruman, D. A., Klee, C. B., Bierer, B. E., & Burakoff, S. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3686 · Cited by 823
Condon, M. B., Ashby, D., Pepper, R. J., Cook, H. T., Levy, J. B., Griffith, M., Cairns, T. D., & Lightstone, L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202844 · Cited by 454
Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1030 · Cited by 396
Mysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., Houssiau, F. A., Drappa, J., Close, D., Maciuca, R., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38037 · Cited by 353
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos‐Vargas, R., Chen, S., Hillson, J. L., Meadows‐Shropshire, S., Kinaszczuk, M., & Merrill, J. T. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38260 · Cited by 341
Self-citationDall'Era, M., Cisternas, M. G., Smilek, D. E., Straub, L., Houssiau, F. A., Cervera, R., Rovin, B. H., & Mackay, M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39026 · Cited by 329
Self-citationThe ACCESS Trial Group (2014) · Arthritis & Rheumatology · doi:10.1002/art.38790 · Cited by 288
Tamirou, F., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Fiehn, C., Ayala Guttierez, M. D. M., Gilboe, I.-M., Tektonidou, M., Blockmans, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206897 · Cited by 216
Wofsy, D., Hillson, J., & Diamond, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34624 · Cited by 165
Tsuda, K., Yamanaka, K., Kitagawa, H., Akeda, T., Naka, M., Niwa, K., Nakanishi, T., Kakeda, M., Gabazza, E. C., & Mizutani, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031465 · Cited by 126
Current and Emerging Therapies for Lupus Nephritis
Parikh, S. V., & Rovin, B. H. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040415 · Cited by 101
Self-citationGunnarsson, I., Sundelin, B., Heimbürger, M., Forslid, J., van Vollenhoven, R., Lundberg, I. E., & Jacobson, S. H. (2002) · PubMed · Cited by 99
Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
Wofsy, D., Hillson, J., & Diamond, B. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37940 · Cited by 95
Shen, X., Jiang, H., Ying, M., Xie, Z., Li, X., Wang, H., Zhao, J., Lin, C., Wang, Y., Feng, S., et al. (2016) · Scientific Reports · doi:10.1038/srep32087 · Cited by 80
Kuglstatter, A., Mueller, F., Kusznir, E. A., Gsell, B., Stihle, M., Thoma, R., Benz, J., Aspeslet, L. J., Freitag, D. G., & Hennig, M. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910051905 · Cited by 53
Fischer‐Betz, R., Chehab, G., Sander, O., Vordenbäumen, S., Voiculescu, A., Brinks, R., & Schneider, M. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.120537 · Cited by 49
Hurdles to the introduction of new therapies for immune-mediated kidney diseases
Anders, H., Jayne, D. R. W., & Rovin, B. H. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.206 · Cited by 49
Self-citationMerino, D., Segundo, D. S., Medina, J. M., Rodrigo, E., Asensio, E., Irure, J., Fernández‐Fresnedo, G., Arias, M., & López‐Hoyos, M. (2016) · Immunology · doi:10.1111/imm.12603 · Cited by 22
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Self-citationFanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Update οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
Rovin, B. H., Teng, Y. K. O., Ginzler, E. M., Arriens, C., Caster, D. J., Romero-Diaz, J., Gibson, K., Kaplan, J., Lisk, L., Navarra, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00578-x · Cited by 635
Self-citation
Metadata
- Authors
- Rovin, B. H., Solomons, N., Pendergraft, W. F., Dooley, M. A., Tumlin, J., Romero-Diaz, J., Lysenko, L., Navarra, S. V., Huizinga, R. B., Adzerikho, I., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Soroka, N., Bogov, B. I., Deliyska, B., Ikonomov, V., Tilkiyan, E., Almeida, R., Jimenez, F., Teran, F., Tchokhonelidze, I., Tsiskarishvili, N., Herrera Mendez, M., Chavez Perez, N. N., Loaeza, A. R., Gutierrez Urena, S. R., Romero Diaz, J., Araiza Casillas, R., Madero Rovalo, M., Niemczyk, S., Sokalski, A., Wiecek, A., Klinger, M., Bugrova, O. V., Chernykh, T. M., Kameneva, T. R., Lysenko, L. V., Raskina, T. A., ReshEtko, O. V., Vezikova, N. N., Kropotina, T. V., Maksudova, A. N., Marasaev, V., Dobronravov, V. A., Gordeev, I., EssAian, A. M., Frolov, A., Jelacic, R., Jovanovic, D., Mitic, B., Pekovic, G., Radovic, M., Radunovic, G., Carreira, P., Diaz Gonzalez, F., Fulladosa, X., Ucar, E., De Silva, S., Herath, C., Hewageegana, A., Nazar, A. L. M., Wazil, A. W. M., Dudar, I., Godlevska, O., Korneyeva, S., Vasylets, V., Sydor, N., Kolesnyk, M., Parikh, S. V., Olsen, N., Ginzler, E. M., Tumlin, J. A., Saxena, A., Saxena, R., Lafayette, R. A., Pendergraft, W. F., Podoll, A. S., Arrey-Mensah, A. A., Bubb, M., Grossman, J., Oporta, A. I., Nami, A., Rahman, M. M., Haq, S. A., Chan, T. M. D., Temy, M. M. Y., Gomez, H. M. P., Bermas, J., Reyes, B. H., Hao, L. T., Roberto, L. C., Amante, E., Navarra, S. V., Lanzon, A. E., Choe, J.-Y., Kang, T. Y., Kim, Y. S., Lee, S.-G., Lee, J. S., Jun, J. C. C., Vasudevan, A., Luo, S.-F., Cheng, T.-T., Satirapoj, B., & Noppakun, K.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 95
- Issue
- 1
- Pages
- 219-231
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2900364017
- Cited by
- 309
- References
- 23
- FWCI
- 23.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.